U.S. Markets closed

Sarepta Therapeutics stock plummets after FDA rejects its muscular dystrophy treatment

Pharmaceutical company Sarepta Therapeutics plunging today after the FDA rejected its second drug for muscular dystrophy. Cantor Fitzgerald lowered its price target for the stock, saying the FDA's decision "could be political." Yahoo Finance's Anjalee Khemlani joins Akiko Fujita.